Impact of extrafine formulation single-inhaler triple therapy on asthma control and treatment adherence after six months of treatment in patients with asthma-TriMaximize study

<bold>Background:</bold> Symptom control and treatment adherence (TA) are fundamental goals of asthma therapy. Clinical trials have demonstrated significant therapeutic benefits of extrafine formulation single-inhaler triple therapy (efSITT) consisting of beclometasone/formoterol/glycopyrronium in the treatment of patients with asthma. The effect of efSITT on asthma control and TA in asthma patients in a real-life setting is not well understood. <bold>Methods:</bold> This observational study follows asthma patients for one to three years after being prescribed efSITT. Asthma control was assessed by the Asthma Control Test (ACT) and TA was evaluated using the Test of Adherence to Inhalers (TAI). <bold>Results:</bold> This interim analysis includes 1090 (63.3% female) patients, majority (75.3%) previously treated with ICS/LABA (open or fixed). Mean ACT score at baseline was 14.7 points. After six months, mean change of ACT from baseline was 3.8 points in the overall population, and 4.1 points in patients on prior ICS/LABA (both p<0.0001), exceeding the minimal clinically important difference of 3 points. At baseline 44.7% of the patients had good adherence, 29.5% had moderate adherence and 25.8% had poor adherence. At six-month follow-up, good and moderate adherence were increased to 48.6% and 32.4%, respectively, while poor adherence was reduced to 19%. Over half (57.5%) of the patients were categorized as TAI responders (improved adherence or good adherence at baseline and after six months). <bold>Conclusions:</bold> Switching from dual as well as free triple combinations significantly improves asthma control and adherence after six months of efSITT.